UNDERSTANDING THE CONCEPT OF DEPRESSION AND PERSPECTIVES OF PHARMACOTHERAPEUTICS IN MODERN CONTEXT
Vikram Singh* and Yogesh Kr. Sharma
ABSTRACT
Chronic, incapacitating depression is quite prevalent. Although beneficial, current pharmacotherapies suffer from significant percentages of little or no response and a lengthy therapeutic time lag. Rapid-acting antidepressants, such as the N-methyl-d-aspartate (NMDA) receptor (NMDAR) antagonist ketamine, that activate many signalling pathways in ways different from those of conventional antidepressants have been the subject of current study. Research into the neurobiology of ketamine and related substances has attracted a lot of attention because of the potential they show for drastically enhancing therapy choices for depressed people. In this article, we summarise what scientists know thus far about rapid-acting antidepressants and their effects on neurons, brain circuits, and signalling pathways.
[Full Text Article] [Download Certificate]